



Figure 1.


A



B



C



D





Figure 2.


A

|                       | Before depletion of CD45/CD31/CD235a |
|-----------------------|--------------------------------------|
| Live singlets         | 61%                                  |
| Non-CD31/45           | 14%                                  |
| Epcam <sup>+</sup>    | 7%                                   |
| HT-II280 <sup>+</sup> | 4.3%                                 |
| HT-II280 <sup>-</sup> | 2.6%                                 |


B



C




D




E

|                       | After depletion of CD45/CD31/CD235a |
|-----------------------|-------------------------------------|
| Live singlets         | 71%                                 |
| Non-CD31/45           | 51.7%                               |
| Epcam <sup>+</sup>    | 33.5%                               |
| HT-II280 <sup>+</sup> | 30%                                 |
| HT-II280 <sup>-</sup> | 3.6%                                |

F



G



H







Figure 3.


**A**

|                   | Before depletion<br>of CD45/<br>CD31/CD235a |
|-------------------|---------------------------------------------|
| Live singlets     | 52%                                         |
| Non-<br>CD31/45   | 17%                                         |
| Epcam             | 9.3%                                        |
| NGFR <sup>+</sup> | 2.7%                                        |
| NGFR <sup>-</sup> | 6.5%                                        |


**B**



**C**




**D**




**E**

|                   | After depletion<br>of CD45/<br>CD31/CD235a |
|-------------------|--------------------------------------------|
| Live singlets     | 79%                                        |
| Non-<br>CD31/45   | 56.6%                                      |
| Epcam             | 38%                                        |
| NGFR <sup>+</sup> | 13%                                        |
| NGFR <sup>-</sup> | 25%                                        |

**F**



**G**



**H**




Figure 4.






Figure 5.

